Free Trial

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Matthew B. Klein Sells 8,279 Shares

PTC Therapeutics logo with Medical background

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) CEO Matthew B. Klein sold 8,279 shares of the business's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $45.16, for a total value of $373,879.64. Following the transaction, the chief executive officer now owns 217,528 shares of the company's stock, valued at $9,823,564.48. This trade represents a 3.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

PTC Therapeutics Stock Up 1.4 %

Shares of PTC Therapeutics stock traded up $0.66 during trading on Friday, hitting $46.54. The stock had a trading volume of 501,601 shares, compared to its average volume of 488,000. The company has a market capitalization of $3.59 billion, a PE ratio of -7.84 and a beta of 0.63. PTC Therapeutics, Inc. has a 1 year low of $23.58 and a 1 year high of $54.16. The stock has a 50 day simple moving average of $44.78 and a 200 day simple moving average of $38.11.

Analyst Ratings Changes

A number of analysts have commented on PTCT shares. The Goldman Sachs Group boosted their price target on shares of PTC Therapeutics from $32.00 to $42.00 and gave the stock a "sell" rating in a research report on Wednesday, December 4th. Barclays boosted their target price on PTC Therapeutics from $45.00 to $56.00 and gave the stock an "equal weight" rating in a report on Tuesday, December 3rd. Citigroup upped their target price on PTC Therapeutics from $26.00 to $32.00 and gave the stock a "sell" rating in a research report on Wednesday, December 4th. Robert W. Baird lifted their price target on PTC Therapeutics from $52.00 to $70.00 and gave the company an "outperform" rating in a research report on Tuesday, December 3rd. Finally, Wells Fargo & Company upped their price objective on PTC Therapeutics from $56.00 to $68.00 and gave the company an "overweight" rating in a report on Tuesday, November 26th. Three investment analysts have rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $54.08.

Get Our Latest Stock Report on PTCT

Institutional Trading of PTC Therapeutics

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in PTC Therapeutics by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,798,666 shares of the biopharmaceutical company's stock valued at $66,743,000 after acquiring an additional 10,886 shares in the last quarter. Two Sigma Advisers LP boosted its holdings in shares of PTC Therapeutics by 10.3% during the third quarter. Two Sigma Advisers LP now owns 429,842 shares of the biopharmaceutical company's stock worth $15,947,000 after purchasing an additional 40,300 shares during the period. Sphera Funds Management LTD. grew its position in PTC Therapeutics by 25.5% during the third quarter. Sphera Funds Management LTD. now owns 118,345 shares of the biopharmaceutical company's stock valued at $4,391,000 after purchasing an additional 24,027 shares in the last quarter. State Street Corp increased its stake in PTC Therapeutics by 5.4% in the 3rd quarter. State Street Corp now owns 2,899,040 shares of the biopharmaceutical company's stock valued at $107,554,000 after buying an additional 149,700 shares during the period. Finally, Point72 Asset Management L.P. lifted its position in PTC Therapeutics by 945.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 575,860 shares of the biopharmaceutical company's stock worth $21,364,000 after buying an additional 643,960 shares in the last quarter.

PTC Therapeutics Company Profile

(Get Free Report)

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Featured Articles

Insider Buying and Selling by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Should You Invest $1,000 in PTC Therapeutics Right Now?

Before you consider PTC Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PTC Therapeutics wasn't on the list.

While PTC Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines